1180 / 1816
Targeting both ER and growth factor receptor
signaling
PI3K/mTOR inhibitors
Everolimus
CDK4/6 inhibition
Palbociclib
Ribociclib
Fibroblast growth factor (FGFR) inhibitors
19-9-2017
Usefulness of endocrine therapy is limited by
common intrinsic and acquired resistance.